Research programme: 161533 TriKE fusion protein - GT Biopharma/Altor BioScience

Drug Profile

Research programme: 161533 TriKE fusion protein - GT Biopharma/Altor BioScience

Alternative Names: 161533; 161533 TriKE fusion protein; 161533 TriKE molecule; CD16/IL-15/CD33; CD16/IL-15/CD33 (161533) tri-specific killer cell engager (TriKE)

Latest Information Update: 10 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Altor BioScience Corporation; OXIS International
  • Developer Altor BioScience Corporation; GT Biopharma
  • Class Antineoplastics; Immunotherapies; Proteins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 07 Aug 2017 Oxis International is now called GT Biopharma
  • 07 Jul 2017 University of Minnesota plans a phase I/II trial for Haematological malignancies (CD33+, Second-line therapy or greater) in USA (IV, infusion) in USA in October 2017 (NCT03214666)
  • 21 Jun 2017 Oxis International and Altor BioScience agree to co-develop 161533 TriKE fusion protein for Haematologic malignancies
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top